(Q36681333)

15 August 2017

1 reference

title

Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria (English)

1 reference

15 August 2017

0 references

Plasmodium falciparum

0 references

lumefantrine

1 reference

based on heuristic

inferred from title

artemether/lumefantrine

1 reference

3

Alexis Nzila

1 reference

15 August 2017

2

Leah Mwai

1 reference

15 August 2017

Gilbert Kokwaro

1

1 reference

PubMed ID

17163809

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

1

1 reference

15 August 2017

75-94

1 reference

Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Artemether-lumefantrine for uncomplicated malaria: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Death and blindness due to overdose of quinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Quinine overdose: review of toxicity and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Complications of quinine poisoning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Neurotoxicity in animals due to arteether and artemether.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

The safety of antimalarial drugs in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Role of arteether in the treatment of malaria and plans for further development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Effects of arteether on an auditory radial-arm maze task in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Neurotoxicity of artemisinin analogs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Artemisinin derivatives: toxic for laboratory animals, safe for humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

A trial of artemether or quinine in children with cerebral malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Ataxia and slurred speech after artesunate treatment for falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Toxic brainstem encephalopathy after artemisinin treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Antimalarial drug resistance and combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Current perspectives on the mechanism of action of artemisinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

A meta-analysis of the association between adherence to drug therapy and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

How do patients use antimalarial drugs? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Feasibility and acceptability of the use of artemether‐lumefantrine in the home management of uncomplicated malaria in children 6–59 months old in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

The difference between effectiveness and efficacy of antimalarial drugs in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Cost effectiveness analysis of strategies to combat malaria in developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

Excretion of mefloquine in human breast milk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.75

21 January 2018

Identifiers

DOI

10.1517/14656566.8.1.75

1 reference

15 August 2017

1 reference

PubMed ID

17163809